At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Adjuvant Therapy for Post/Perimenopausal Patients With Node Positive Breast Cancer Who Are Suitable for Endocrine Therapy Alone.
In Brief
A Phase 3 clinical trial evaluating cyclophosphamide, doxorubicin hydrochloride, and 3 other interventions for Breast Cancer. Completed, enrolled 452 participants across 20 sites in 7 countries.
Detailed Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy may fight breast cancer by blocking the uptake of estrogen. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of hormone therapy during or after combination chemotherapy or hormone therapy alone in treating perimenopausal or postmenopausal women who have stage II or stage IIIA breast cancer.
Study Details
Timeline
Interventions
cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
Tamoxifen 20 mg daily.
Toremifene 60 mg daily.